Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25751510 | 0.98 | MEN1 (0.71) | MEN1KMT2ADNM1KDM4ECASP2 | |
| SCHEMBL7159679 | 0.92 | MEN1 (0.67) | MEN1KMT2ADNM1KDM4EPAOX | |
| Hydrochloric Acid SCHEMBL30988427 | 0.90 | MEN1 (0.64) | MEN1KMT2ADNM1KDM4EPAOX | |
| SCHEMBL25817165 | 0.88 | MEN1 (0.68) | MEN1KMT2ADNM1KDM4ECASP2 | |
| SCHEMBL25816679 | 0.86 | MEN1 (0.71) | MEN1KMT2ADNM1CASP2ALDH1A1 | |
| SCHEMBL9259257 | 0.85 | MEN1 (0.94) | MEN1KMT2AKDM4ECASP2ALDH1A1 | |
| SCHEMBL21765846 | 0.85 | MEN1 (0.94) | MEN1KMT2AKDM4ECASP2ALDH1A1 | |
| SCHEMBL11758762 | 0.85 | MEN1 (0.94) | MEN1KMT2AKDM4ECASP2ALDH1A1 | |
| SCHEMBL25816837 | 0.84 | MEN1 (0.68) | MEN1KMT2ADNM1CASP2ALDH1A1 | |
| SCHEMBL27450160 | 0.84 | DNM1 (0.65) | MEN1KMT2ADNM1KDM4ECASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | IL17A, IL15, IL2 | MEN1 1132/4885KMT2A 3399/4885DNM1 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.